Radhakrishnan Vijayababu M, Gilpatrick Maryam M, Parsa Nour Alhoda, Kiela Pawel R, Ghishan Fayez K
Department of Pediatrics, The University of Arizona, Tucson, Arizona; and.
Department of Pediatrics, The University of Arizona, Tucson, Arizona; and
Am J Physiol Gastrointest Liver Physiol. 2017 Jan 1;312(1):G77-G84. doi: 10.1152/ajpgi.00394.2016. Epub 2016 Dec 8.
It has been hypothesized that apically expressed L-type Ca channel Ca1.3 (encoded by CACNA1D gene) contributes toward an alternative TRPV6-independent route of intestinal epithelial Ca absorption, especially during digestion when high luminal concentration of Ca and other nutrients limit TRPV6 contribution. We and others have implicated altered expression and activity of key mediators of intestinal and renal Ca (re)absorption as contributors to negative systemic Ca balance and bone loss in intestinal inflammation. Here, we investigated the effects of experimental colitis and related inflammatory mediators on colonic Ca1.3 expression. We confirmed Ca1.3 expression within the segments of the mouse and human gastrointestinal tract. Consistent with available microarray data (GEO database) from inflammatory bowel disease (IBD) patients, mouse colonic expression of Ca1.3 was significantly reduced in trinitrobenzene sulfonic acid (TNBS) colitis. In vitro, IFNγ most potently reduced Ca1.3 expression. We reproduced these findings in vivo with wild-type and Stat1 mice injected with IFNγ. The observed effect in Stat1 suggested a noncanonical transcriptional repression or a posttranscriptional mechanism. In support of the latter, we observed no effect on the cloned Ca1.3 gene promoter activity and accelerated Ca1.3 mRNA decay rate in IFNγ-treated HCT116 cells. While the relative contribution of Ca1.3 to intestinal Ca absorption and its value as a therapeutic target remain to be established, we postulate that Ca1.3 downregulation in IBD may contribute to the negative systemic Ca balance, to increased bone resorption, and to reduced bone mineral density in IBD patients.
据推测,顶端表达的L型钙通道Ca1.3(由CACNA1D基因编码)有助于肠道上皮细胞钙吸收的另一种不依赖瞬时受体电位香草酸亚型6(TRPV6)的途径,特别是在消化过程中,当管腔中高浓度的钙和其他营养物质限制TRPV6的作用时。我们和其他人已经指出,肠道和肾脏钙(再)吸收的关键介质的表达和活性改变是导致肠道炎症中全身钙负平衡和骨质流失的原因。在这里,我们研究了实验性结肠炎和相关炎症介质对结肠Ca1.3表达的影响。我们证实了Ca1.3在小鼠和人类胃肠道各段中的表达。与炎性肠病(IBD)患者可用的微阵列数据(基因表达综合数据库)一致,在三硝基苯磺酸(TNBS)诱导的结肠炎中,小鼠结肠Ca1.3的表达显著降低。在体外,γ干扰素(IFNγ)最有效地降低了Ca1.3的表达。我们在注射IFNγ的野生型和Stat1基因敲除小鼠体内再现了这些发现。在Stat1基因敲除小鼠中观察到的效应提示了一种非经典的转录抑制或转录后机制。为支持后者,我们观察到IFNγ处理的HCT116细胞中,克隆的Ca1.3基因启动子活性没有受到影响,而Ca1.3 mRNA的衰减速率加快。虽然Ca1.3对肠道钙吸收的相对贡献及其作为治疗靶点的价值仍有待确定,但我们推测IBD中Ca1.3的下调可能导致全身钙负平衡、骨吸收增加以及IBD患者骨矿物质密度降低。